Studies aiming at elucidating metformin’s anti-cancer properties have revealed a complex interplay with different molecular targets, including adenosine monophosphate-activated protein kinase (AMPK), mammalian target of rapamycin (mTOR) complex 1 and complex I of the mitochondrial electron transport chain (ETC) [5]. Here, MTOR is linked to cancer.